Ronald Blue & Company Has Decreased Eli Lilly & Company (LLY) Position By $332,442; Shorts at Novavax (NVAX) Raised By 1.84%

July 17, 2017 - By Ellis Scott

Novavax Incorporated (NASDAQ:NVAX) had an increase of 1.84% in short interest. NVAX’s SI was 64.28M shares in July as released by FINRA. Its up 1.84% from 63.12M shares previously. With 4.54M avg volume, 14 days are for Novavax Incorporated (NASDAQ:NVAX)’s short sellers to cover NVAX’s short positions. The SI to Novavax Incorporated’s float is 24.06%. It closed at $1.17 lastly. It is down 79.61% since July 17, 2016 and is downtrending. It has underperformed by 96.31% the S&P500.

Ronald Blue & Company Llc decreased Eli Lilly & Company (LLY) stake by 8.3% reported in 2016Q4 SEC filing. Ronald Blue & Company Llc sold 4,554 shares as Eli Lilly & Company (LLY)’s stock declined 3.22%. The Ronald Blue & Company Llc holds 50,323 shares with $3.70M value, down from 54,877 last quarter. Eli Lilly & Company now has $93.43 billion valuation. The stock declined 0.77% or $0.65 reaching $83.7 per share. About 11 shares traded. Eli Lilly and Co (NYSE:LLY) has risen 4.70% since July 17, 2016 and is uptrending. It has underperformed by 12.00% the S&P500.

Investors sentiment decreased to 0.61 in 2016 Q4. Its down 0.33, from 0.94 in 2016Q3. It turned negative, as 40 investors sold Novavax, Inc. shares while 45 reduced holdings. 20 funds opened positions while 32 raised stakes. 140.95 million shares or 14.83% less from 165.50 million shares in 2016Q3 were reported. Massmutual Trust Fsb Adv reported 673 shares or 0% of all its holdings. Oxford Asset Mgmt holds 0.01% in Novavax, Inc. (NASDAQ:NVAX) or 84,725 shares. Massachusetts-based Eventide Asset Management Lc has invested 0.12% in Novavax, Inc. (NASDAQ:NVAX). State Board Of Administration Of Florida Retirement Systems holds 0% of its portfolio in Novavax, Inc. (NASDAQ:NVAX) for 141,673 shares. Morgan Stanley reported 3.36 million shares stake. Aperio Gp Ltd Llc reported 29,509 shares. Rock Springs Ltd Partnership accumulated 820,000 shares. Financial Bank Of America Corp De owns 180,554 shares or 0% of their US portfolio. Citigroup reported 1.31M shares stake. Coldstream Capital Mgmt holds 0% of its portfolio in Novavax, Inc. (NASDAQ:NVAX) for 15,000 shares. Credit Suisse Ag has invested 0% in Novavax, Inc. (NASDAQ:NVAX). Edge Wealth Management Limited Liability Com reported 0% in Novavax, Inc. (NASDAQ:NVAX). Ing Groep Nv holds 0% or 20,000 shares in its portfolio. National Bank Of Mellon stated it has 0% of its portfolio in Novavax, Inc. (NASDAQ:NVAX). 40,944 were reported by Tudor Investment Et Al.

Among 9 analysts covering Novavax (NASDAQ:NVAX), 2 have Buy rating, 0 Sell and 7 Hold. Therefore 22% are positive. Novavax had 12 analyst reports since August 11, 2015 according to SRatingsIntel. The firm has “Neutral” rating by Chardan Capital Markets given on Monday, April 4. Piperjaffray downgraded it to “Neutral” rating and $1 target in Friday, September 16 report. The rating was downgraded by Wedbush to “Neutral” on Friday, September 16. The stock of Novavax, Inc. (NASDAQ:NVAX) earned “Overweight” rating by Piper Jaffray on Tuesday, August 11. The firm has “Neutral” rating by Citigroup given on Monday, September 19. The rating was maintained by FBR Capital with “Outperform” on Friday, September 16. The rating was downgraded by Ladenburg Thalmann to “Neutral” on Friday, September 16. The firm has “Neutral” rating by Citigroup given on Friday, September 16. The rating was downgraded by JP Morgan on Friday, September 16 to “Neutral”. The stock has “Neutral” rating by Chardan Capital Markets on Tuesday, September 20.

Novavax, Inc. is a clinical-stage vaccine firm focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The company has market cap of $330.66 million. The Firm operates through developing recombinant vaccines segment. It currently has negative earnings. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

Since January 31, 2017, it had 3 buys, and 1 sale for $127,787 activity. 3,401 Novavax, Inc. (NASDAQ:NVAX) shares with value of $3,809 were bought by Trizzino John. The insider PHILLIPS BARCLAY A bought $1,829. $138,980 worth of stock was sold by YOUNG JAMES F on Tuesday, March 14. Herrmann John A III also bought $5,555 worth of Novavax, Inc. (NASDAQ:NVAX) shares.

Analysts await Eli Lilly and Co (NYSE:LLY) to report earnings on July, 25 before the open. They expect $1.03 EPS, up 19.77% or $0.17 from last year’s $0.86 per share. LLY’s profit will be $1.15B for 20.32 P/E if the $1.03 EPS becomes a reality. After $0.98 actual EPS reported by Eli Lilly and Co for the previous quarter, Wall Street now forecasts 5.10% EPS growth.

Ronald Blue & Company Llc increased Ishares Gs Inv. Top (LQD) stake by 5,221 shares to 19,290 valued at $2.26 million in 2016Q4. It also upped Ishares Barclays 0 (STIP) stake by 5,531 shares and now owns 7,682 shares. Vanguard Ftse Europe Etf (VGK) was raised too.

Investors sentiment decreased to 0.97 in 2016 Q4. Its down 0.11, from 1.08 in 2016Q3. It dived, as 84 investors sold LLY shares while 380 reduced holdings. 103 funds opened positions while 348 raised stakes. 809.72 million shares or 0.51% more from 805.63 million shares in 2016Q3 were reported. 455,920 were reported by Virginia Retirement Sys Et Al. 5,377 were reported by Legacy Private Trust. Logan Cap Mgmt has invested 0.16% in Eli Lilly and Co (NYSE:LLY). Clarkston Prtn Lc holds 10,000 shares. Da Davidson And holds 0.06% or 37,086 shares. Choate Invest holds 23,712 shares. Tiaa Cref Inv Management Ltd Com invested in 8.07M shares. Douglass Winthrop Advisors Ltd Llc reported 0.02% stake. Sandy Spring Comml Bank accumulated 0.01% or 1,448 shares. Blb&B Advsrs Ltd Liability Corp invested in 0.11% or 8,780 shares. King Wealth Mgmt Limited Liability owns 0.09% invested in Eli Lilly and Co (NYSE:LLY) for 2,725 shares. Franklin Resource owns 34.74M shares. Bokf Na stated it has 48,538 shares or 0.12% of all its holdings. Walter Keenan Consulting Mi Adv reported 1.91% in Eli Lilly and Co (NYSE:LLY). Patten Patten Tn stated it has 0.07% in Eli Lilly and Co (NYSE:LLY).

Since February 1, 2017, it had 0 insider purchases, and 9 sales for $59.49 million activity. $155,040 worth of stock was sold by Zakrowski Donald A on Thursday, February 2. LILLY ENDOWMENT INC had sold 220,000 shares worth $17.02M. 22,833 shares valued at $1.83M were sold by Harrington Michael J on Friday, June 9. Zulueta Alfonso G had sold 15,000 shares worth $1.16 million on Monday, February 6. Rice Derica W also sold $861,085 worth of Eli Lilly and Co (NYSE:LLY) shares. Conterno Enrique A had sold 25,000 shares worth $2.07M on Thursday, May 4. On Monday, June 12 Barnes Melissa S sold $153,482 worth of Eli Lilly and Co (NYSE:LLY) or 1,900 shares.

Among 17 analysts covering Eli Lilly and Company (NYSE:LLY), 13 have Buy rating, 1 Sell and 3 Hold. Therefore 76% are positive. Eli Lilly and Company had 56 analyst reports since July 23, 2015 according to SRatingsIntel. The stock has “Outperform” rating by Cowen & Co on Monday, August 24. The firm has “Buy” rating given on Friday, September 18 by Bank of America. The rating was maintained by Jefferies on Tuesday, May 30 with “Buy”. The firm earned “Buy” rating on Tuesday, September 27 by Goldman Sachs. The company was maintained on Thursday, July 14 by Jefferies. The stock of Eli Lilly and Co (NYSE:LLY) earned “Hold” rating by Argus Research on Thursday, April 27. The rating was maintained by Jefferies with “Buy” on Friday, June 16. On Saturday, August 22 the stock rating was maintained by Cowen & Co with “Outperform”. Societe Generale initiated Eli Lilly and Co (NYSE:LLY) on Wednesday, April 6 with “Hold” rating. The company was maintained on Wednesday, June 14 by SunTrust.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: